Industry News
UK's GM crop trials not relevant to us: CSIRO
The findings of a British study of the impact of genetically modified, herbicide-tolerant (GMHT) crops on farm biodiversity are critical to the future of GM crops in Britain, but have little relevance to Australia, CSIRO experts have concluded. [ + ]
Biotech heavyweights join Alchemia board
Brisbane firm Alchemia has beefed up its board with the appointments of seasoned biotechnology executive Mel Bridges as chairman and two new non-executive directors, including ex-Amgen consultant Dr Errol Malta and former Minter Ellison lawyer Nerolie Withnall. [ + ]
Pharmaxis closes IPO oversubscribed
Sydney-based Pharmaxis closed its IPO yesterday, three days earlier than scheduled after strong demand from investors. [ + ]
Ventracor raises $33m in rights issue
Ventracor (ASX:VCR) has closed its renounceable rights issue, raising approximately AUD$33 million in an offer oversubscribed by $12 million. [ + ]
BresaGen in $5m bridging finance bid
Adelaide biotech BresaGen (ASX:BGN) is attempting to boost its cash reserves by up to AUD$5 million through a private placement of convertible preference shares, managed by PricewaterhouseCoopers Securities. [ + ]
BioProspect buys trader to boost distribution prospects
Brisbane biopesticide developer BioProspect (ASX:BPO) has moved to establish itself as a significant player in the biotech business by acquiring agrochemical trader Tradewyns as a vehicle to distribute its products. [ + ]
BTG International backs coeliac disease JV
A vaccine for coeliac disease is the focus of a joint venture between the Royal Melbourne Hospital, Melbourne Health and the Walter and Eliza Hall Institute of Medical Research (WEHI), in a project that has the backing of international VC group BTG International. [ + ]
EpiTan reports "outstanding" results for Melanotan
Melbourne biotech EpiTan Ltd (ASX: EPT) has announced "outstanding" results from the Phase IIb clinical of its experimental tanning drug Melanotan - and says the data could be the subject of new patent applications. [ + ]
Gradipore to refocus on commercialising its technology
After several tumultuous days that saw almost the entire board of directors replaced, bio-separations company Gradipore said today that it plans to focus on commercialising its technology for large-scale separations. [ + ]
Could you suffer from psychosis? The nose knows
Your nose could provide the first reliable diagnostic tool for predicting a person's likelihood of developing psychosis, new research has found.
[ + ]C3, Equipmed sign distribution agreements
Perth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand. [ + ]
Amrad aims to regain its footing
If you'd asked him a year ago whether he could see himself as CEO of Amrad, Dr Peter Smith would have said not likely. [ + ]
Panbio announces alliance with Adaltis
Diagnostics company Panbio has announced a strategic alliance with Canadian-based medical diagnostics instrumentation group Adaltis to develop automated diagnostic products. [ + ]
Gradipore faces shareholder-driven rebellion
Just weeks after a new CEO was appointed, embattled bioseparations company Gradipore has lost almost its entire board of directors in a shareholder-driven rebellion against the management of the company. [ + ]
Cotton researcher top Aussie scientist
CSIRO Plant Industry's leader of cotton research in Narrabri NSW, Dr Greg Constable, is Australia's smartest scientist, according to The Bulletin magazine.
[ + ]